– USA, WA – Acucela Inc., a clinical-stage ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., announced today that it has appointed Bob Stevens to its Board of Directors.
“Bob’s 33 years of experience in the ophthalmology field will bring valuable perspectives to the Board and provide Acucela with a strong background in product research and design. His extensive work as a head of business development as well as R&D is very impressive and we are very fortunate to have Bob as our Board of Directors, as we continue to grow and evolve, addressing unmet needs for patients with eye disease,” stated Ryo Kubota, MD, PhD, and Chairman, President and CEO of Acucela.
About Bob Stevens
Mr. Stevens is currently Chief Technology Officer at CorneaGen, based in Seattle, WA, specialized in cornea care through medical devices and biologics. Previously, he worked at Novartis/Alcon Laboratories for nearly 35 years. During his tenure, he spent more than 20 years leading all research and design for surgical products in the field of ophthalmology. The technology he helped bring to market significantly impacted the practice of medicine and positioned Alcon as the leading company in the manufacturing of ophthalmic surgical products. Mr. Stevens introduced several industry-leading innovations, including a proprietary intraocular lens material, AcrySof, along with proprietary intraocular lens designs, Viscoelastics and surgical instruments for both anterior and posterior segment surgery.
Mr. Stevens’ experience in eye banking dates back to 1991 when he received the Thoth Award for his role in developing a plan to support U.S. eye banks during a crisis involving cornea preservative storage media. The storage media used by 80 percent of the market was recalled due to bacterial contamination, but the plan Mr. Stevens developed with partners prevented a shut down of the corneal transplant business in the U.S.
Mr. Stevens stated, “I am looking forward to working with the other Board members, in helping Dr. Kubota realize his vision. I believe my background and experience complement that of the other Board members.”
Mr. Stevens has served on the University of Washington Eye Institute Community Action Board. He earned his bachelor’s degree in medical technology and his master’s degree in clinical microbiology from the University of Washington.
About Acucela Inc.
Acucela Inc. is a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Acucela’s development pipeline includes drug candidates for the treatment of diabetic retinopathy, diabetic macular edema, Stargardt disease, age-related macular degeneration, cataracts and presbyopia, and, optogenetics-based gene therapy for the treatment of retinitis pigmentosa. The company is also developing a handheld OCT device for the monitoring of neovascular retinal diseases, to be used directly by patients.
For more information: https://www.acucela.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.